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ABSTRACT 
Retinal gene therapy with adeno-associated viral (AAV) vectors is safe and effective 
in humans. However, AAV’s limited cargo capacity prevents its application to 
therapies of inherited retinal diseases due to mutations of genes over 5 kb, like 
Stargardt's disease (STGD) and Usher syndrome type IB (USH1B). Previous methods 
based on “forced” packaging of large genes into AAV capsids may not be easily 
translated to the clinic due to the generation of genomes of heterogeneous size which 
raise safety concerns. Taking advantage of AAV’s ability to concatemerize, we 
generated dual AAV vectors which reconstitute a large gene by either splicing (trans-
splicing), homologous recombination (overlapping), or a combination of the two 
(hybrid). We found that dual trans-splicing and hybrid vectors transduce efficiently 
mouse and pig photoreceptors to levels that, albeit lower than those achieved with a 
single AAV, resulted in significant improvement of the retinal phenotype of mouse 
models of STGD and USH1B. Thus, dual AAV trans-splicing or hybrid vectors are an 
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INTRODUCTION 
Inherited retinal degenerations (IRDs), with an overall global prevalence of 1/2.000 
(Sohocki et al, 2001), are a major cause of blindness worldwide. Among the most 
frequent and severe IRDs are retinitis pigmentosa (RP), Leber congenital amaurosis 
(LCA), and Stargardt’s disease (STGD), which are most often inherited as monogenic 
conditions. The majority of mutations causing IRDs occur in genes expressed in 
neuronal photoreceptors (PR), rods and/or cones in the retina (Dryja, 2001). No 
therapy is currently available for these blinding diseases. 
Gene therapy holds great promise for the treatment of IRDs. Among the available 
gene transfer vectors, those based on the small adeno-associated virus (AAV) are 
most efficient at targeting both PR and retinal pigment epithelium (RPE) for long-
term treatment upon a single subretinal administration (Colella et al, 2009; 
Vandenberghe & Auricchio, 2012). Recently we and others, have demonstrated that 
subretinal administration of AAV is well-tolerated and effective for improving vision 
in patients affected with type 2 LCA, which is caused by mutations in RPE65, a gene 
expressed in the RPE (Bainbridge et al, 2008; Cideciyan et al, 2009; Maguire et al, 
2009; Maguire et al, 2008; Simonelli et al, 2010). These results bode well for the 
treatment of other forms of LCA and IRDs in general. The availability of AAV vector 
serotypes such as AAV2/8, which efficiently targets PR (Allocca et al, 2007; 
Auricchio, 2011; Mussolino et al, 2011; Natkunarajah et al, 2008; Vandenberghe et al, 
2011) and RPE, further supports this approach. However, a major limitation of AAV 
is its cargo capacity, which is thought to be limited to around 5 kb, the size of the 
parental viral genome (Dong et al, 2010a; Hermonat et al, 1997; Lai et al, 2010; 
Wang et al, 2012; Wu et al, 2010b). This limits the application of AAV gene therapy 
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sequence (CDS) is larger than 5 kb (herein referred to as large genes). These include: 
i. STGD (MIM#248200), the most common form of inherited macular degeneration 
caused by mutations in the ABCA4 gene (CDS: 6822 bp) (Allikmets, 1997), which 
encodes the all-trans retinal transporter located in the PR outer segment (Allikmets, 
1997; Molday & Zhang, 2010); ii. Usher syndrome type IB (USH1B; MIM#276900), 
the most severe form of RP and deafness caused by mutations in the MYO7A gene 
(CDS: 6648 bp) (Millan et al, 2011) encoding the unconventional MYO7A, an actin-
based motor expressed in both PR and RPE within the retina (Gibbs et al, 2010; 
Hasson et al, 1995; Liu et al, 1997). 
Various strategies have been investigated to overcome the limitation of AAV cargo 
capacity. Several groups, including our own, have attempted to "force" large genes 
into one of the many AAV capsids available by developing the so-called oversize 
vectors (Allocca et al, 2008; Grieger & Samulski, 2005; Wu et al, 2007). Although 
administration of oversize AAV vectors achieves therapeutically-relevant levels of 
transgene expression in rodent and canine models of human inherited diseases 
(Allocca et al, 2008; Grose et al, 2012; Lopes et al, 2013; Monahan et al, 2010), 
including the retina of the Abca4-/- and shaker 1 (sh1) mouse models of STGD and 
USH1B (Allocca et al, 2008; Lopes et al, 2013), the mechanism underlying oversize 
AAV-mediated transduction remains elusive. In contrast to what we and others 
originally proposed (Allocca et al, 2008; Grieger & Samulski, 2005; Wu et al, 2007), 
oversize AAV vectors do not contain a pure population of intact large size genomes 
but rather a heterogeneous mixture of mostly truncated genomes ≤5kb in length 
(Dong et al, 2010a; Lai et al, 2010; Wang et al, 2012; Wu et al, 2010b). Following 
infection, re-assembly of these truncated genomes in the target cell nucleus has been 
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Hirsch et al, 2010; Hirsch et al, 2013; Lai et al, 2010; Wu et al, 2010b). Independent 
of transduction mechanism and in vivo efficacy, the heterogeneity in oversize AAV 
genome sizes is a major limitation for their application in human gene therapy.  
Alternatively, the inherent ability of AAV genomes to undergo intermolecular 
concatemerization (Duan et al, 1998) is exploited to transfer large genes in vivo by 
splitting a large gene expression cassette into halves (<5kb in size), each contained in 
one of two separate (dual) AAV vectors (Duan et al, 2001; Ghosh et al, 2008; Yan et 
al, 2000). In the dual AAV trans-splicing strategy, a splice donor (SD) signal is placed 
at the 3’ end of the 5’-half vector and a splice acceptor (SA) signal is placed at the 5’ 
end of the 3’-half vector (Fig. 1). Upon co-infection of the same cell by the dual AAV 
vectors and inverted terminal repeat (ITR)-mediated head-to-tail concatemerization of 
the two halves, trans-splicing results in the production of a mature mRNA and full-
size protein (Yan et al, 2000). Trans-splicing has been successfully used to express 
large genes in muscle and retina (Lai et al, 2005; Reich et al, 2003). Alternatively, the 
two halves of a large transgene expression cassette contained in dual AAV vectors 
may contain homologous overlapping sequences (at the 3’ end of the 5’-half vector 
and at the 5’ end of the 3’-half vector, dual AAV overlapping), which will mediate 
reconstitution of a single large genome by homologous recombination (Duan et al, 
2001). This strategy depends on the recombinogenic properties of the transgene 
overlapping sequences (Ghosh et al, 2006). A third dual AAV strategy (hybrid) is 
based on adding a highly recombinogenic region from an exogenous gene [i.e. 
alkaline phosphatase, AP (Ghosh et al, 2011; Ghosh et al, 2008)] to the trans-splicing 
vector. The added region is placed downstream of the SD signal in the 5'-half vector 
and upstream of the SA signal in the 3'-half vector (Fig. 1) in order to increase 
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To determine which AAV-based strategy most efficiently transduces large genes in 
the retina, we compared them side-by-side in HEK293 cells and in mouse and pig 
retina in vivo using EGFP, ABCA4 or MYO7A. We then used the dual AAV trans-
splicing and hybrid strategies, which were the most efficient for transducing PR as 
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RESULTS 
Generation of normal size, oversize and dual AAV vectors. 
We generated AAV oversize (OZ), dual AAV overlapping (OV), dual AAV trans-
splicing (TS) and hybrid vectors that included the therapeutic ABCA4-3xflag and 
MYO7A-HA coding sequences. The recombinogenic sequences included in the dual 
AAV hybrid vectors were based on either a previously reported region of the alkaline 
phosphatase transgene (AP, dual AAV hybrid AP) (Ghosh et al, 2011) or a 77 bp 
sequence from the F1 phage genome (AK, dual AAV hybrid AK) that we found to be 
recombinogenic in previous in vitro experiments (Colella and Auricchio, unpublished 
data). We additionally generated AAV OZ and dual AAV vectors including the 
reporter EGFP sequence with the exception of the dual AAV OV approach since its 
efficiency relies on transgene-specific overlaps for reconstitution (Ghosh et al, 2006) 
and therefore can not be extrapolated from one gene to another. For EGFP we 
additionally generated single AAV vectors of normal size (NS) to compare levels of 
transgene expression from the various strategies. The constructs generated for 
production of all AAV vectors used in this study are listed in Supporting Table 1 and 
a schematic representation of the various approaches is depicted in Figure 1. 
We used AAV2/2 vectors for the in vitro experiments, with the ubiquitous 
cytomegalovirus (CMV) or chicken beta-actin (CBA) promoters, which efficiently 
transduce HEK293 cells (Dong et al, 2010b). In the experiments performed in vivo in 
the retina, we used AAV2/8 vectors, which efficiently transduce RPE and PR 
(Allocca et al, 2007; Mussolino et al, 2011; Vandenberghe et al, 2011) but poorly 
infect HEK293 cells, and either the ubiquitous CBA and CMV promoters (Mussolino 
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al, 2004) or the PR-specific Rhodopsin (RHO) and Rhodopsin kinase (RHOK) 
promoters (Allocca et al, 2007) (Supp. Table 1).  
 
Dual AAV vectors allow high levels of transduction in vitro. 
We initially compared the efficiency of the various OZ, dual AAV OV, TS and hybrid 
AP and AK strategies for AAV-mediated large gene transduction in vitro by infecting 
HEK293 cells with the AAV2/2 vectors [multiplicity of infection, m.o.i.: 105 genome 
copies (GC)/cell of each vector] with ubiquitous promoters (CMV for ABCA4-3xflag, 
CBA for MYO7A-HA). Cell lysates were analyzed by Western blot with anti-3xflag 
(to detect ABCA4-3xflag, Fig. 2A) or anti-Myo7a (Fig. 2B) antibodies. All strategies 
resulted in the expression of proteins of the expected size. As predicted, no bands of 
the expected size were observed when only one of the dual AAV vectors was used for 
infection (Fig. 2A-B). Quantification of ABCA4 and MYO7A expression (Fig. 2D-E) 
showed that the dual AAV hybrid AP approach resulted in the lowest levels of 
transgene expression, while the dual AAV OV, TS and hybrid AK approaches were 
more efficient than the AAV OZ approach. We then confirmed this using the EGFP 
transgene. For this purpose we selected the best performing dual AAV strategies (TS 
and hybrid AK; we did not use the transgene-specific OV strategy with EGFP, which 
is a reporter gene) and further compared them to AAV OZ. We thus produced 
AAV2/2-CMV-OZ-EGFP vectors and for comparison -TS- and -AK-EGFP-L in 
which the combined dual AAV vector genome length is similar to that of AAV OZ 
(Supp. Table 1). We infected HEK293 cells with AAV2/2-CMV-EGFP vectors 
[multiplicity of infection, m.o.i.: 105 genome copies (GC)/cell of each vector] and 
performed Western blot analysis of cell lysates with anti-EGFP antibodies (Fig. 2C). 
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of EGFP expression (Fig. 2F) showed that dual AAV TS and hybrid AK approaches 
are more efficient than AAV OZ.  
Then, we compared the efficiency of single AAV NS-EGFP to that of dual AAV TS 
and hybrid AK of similar size (Supp. Fig. 1) by Western blot analysis of infected 
HEK293 cells. Quantification of EGFP expression showed that the levels achieved 
with dual AAV TS and hybrid AK were about 13-25 folds lower (7-4%) than with 
AAV NS (Supp. Fig. 1). 
 
Dual AAV TS and hybrid AK but not OV vectors transduce mouse and pig 
photoreceptors. 
The enclosed and small subretinal space should favour co-infection and transduction 
of the same cell by two independent AAV vectors. To test this, we injected 
subretinally WT mice with AAV2/8-CMV-EGFP, AAV2/8-CMV-DsRed or a mixture 
of both vectors (dose of each vector/eye: 3x109 GC) and harvested the eyes 
transduced by single or both vectors 3 weeks post-injection. Neural retinas, separated 
from the RPE, were dissociated and analyzed by flow cytometry. We found that 
36±6% of the labeled cells were positive for both EGFP and DsRed. However, since 
the number of DsRed+ only cells (8±5% ) was lower than the number of EGFP+ only 
cells (56±8%) by counting the number of EGFP+/DsRed+ cells over the total number 
of transduced cells we may have under-estimated the co-transduction efficiency of the 
two vectors. Indeed, if we analyze the DsRed-positive cell populations, 82% of these 
were also EGFP-positive. This co-transduction efficiency is similar to that which we 
have reported previously (Palfi et al, 2012). To determine the co-transduction 
efficiency specifically in PR, and to test another red fluorescent reporter possibly 
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AAV2/8-CMV-EGFP and -RFP vectors (dose of each vector/eye: 1.4x109 GC/eye) 
and analyzed co-transduction on retinal cryosections which allow to inequivocably 
identify PR from RPE (Supp. Fig. 2). We found that 24±2% of transduced PR 
expressed both EGFP and RFP. However, the number of RFP+ cells was still lower 
than the number of EGFP+ cells due to weaker RFP fluorescence compared to EGFP, 
and the percentage of co-transduction reaches 53±4% when we consider the number 
of RFP+ cells that are also EGFP+.  
We then evaluated the best in vitro performing AAV-based systems for large gene 
transduction in the mouse retina. To test the dual AAV OV, which is transgene-
specific, we used the therapeutic ABCA4 and MYO7A genes (Fig. 3 and data not 
shown). We used EGFP to evaluate the AAV OZ and the dual AAV TS and hybrid 
AK approaches (Supp. Fig. 4).  
Western blot analysis on retinal lysates, one month after subretinal delivery in 
C57BL/6 mice of the dual AAV OV vectors (dose of each vector/eye: 1.3x109 GC), 
encoding ABCA4-3xflag from the ubiquitous CMV promoter, revealed robust protein 
expression (Fig. 3A). To determine which cell type in the retina expressed ABCA4, 
we used dual AAV OV vectors that contained either the PR-specific RHO and RHOK, 
or the RPE-specific VMD2 (dose of each vector/eye: 1x109 GC) promoters. We 
detected ABCA4 protein expression in retinas injected with the VMD2 but not in 
those containing the RHO and RHOK promoters (Fig. 3A). These results were also 
confirmed in the Large White pig retina (Fig. 3B). The pig retina is an excellent 
model to evaluate vector efficiency because of its size, which is similar to the human 
retina, and because it is enriched with cones that are concentrated in a streak-like 
region whose cone density is comparable to that of the primate macula (Mussolino et 
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encoding ABCA4-3xflag (dose of each vector/eye: 1x1010 GC), and observed ABCA4 
protein expression with the CMV but not the RHO promoter (Fig. 3B). Similarly, 
subretinal administration of dual AAV OV vectors encoding MYO7A-HA resulted in 
weak MYO7A protein expression in the mouse retina with the ubiquitous CBA (dose 
of each vector/eye: 2.5x109 GC) and no detectable expression with the RHO (dose of 
each vector/eye: 3.2x109 GC) promoter (data not shown). To rule out that this was due 
to a lower transcriptional activity from either the RHO or RHOK promoters compared 
to CMV, we injected subretinally C57BL/6 mice with 1.5x109 GC/eye of AAV2/8 
vectors expressing EGFP from each of the promoters and found that CMV and RHO 
drive similarly robust PR transgene expression (Supp. Fig. 3). Overall, these data 
suggest that the dual AAV OV approach is more efficient for large gene transfer to 
RPE than to PR.  
To find an AAV-based strategy that efficiently transduces large genes in PR, which 
are a major target of gene therapy for IRDs including STGD and USH1B, we 
compared the retinal transduction properties of the AAV OZ with those of dual AAV 
TS and hybrid AK approaches, which in addition to dual AAV OV were the best 
performing dual AAV approaches in vitro. We used EGFP, which allowed us to easily 
localize transgene expression in the various retinal cell types, including PR, as well as 
to properly compare the levels of AAV-based large transgene transduction to those of 
a single AAV NS vector. C57BL/6 mice were initially injected subretinally with AAV 
OZ and dual AAV TS-L and hybrid AK-L vectors (dose of each vector/eye: 1.7x109 
GC), all encoding EGFP under the transcriptional control of the CMV promoter. One 
month later, fundus photographs showed that the highest levels of fluorescence were 
obtained with the dual AAV TS and hybrid AK approaches (Supp. Fig. 4A). 
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levels of RPE and PR transduction could be achieved with all approaches when 
combining the two half-vectors but not with each of them separately (Supp. Fig. 4B 
and 5). However the levels of expression were higher, although variable, in the eyes 
injected with dual AAV TS-L and hybrid AK-L than in the eyes injected with AAV 
OZ vectors (Supp. Fig. 4).  
To test whether the levels and consistency of dual AAV-mediated transduction 
obtained can be improved by varying the ratio between the 5’- and 3’-half vectors, we 
injected subretinally C57BL/6 mice with dual AAV TS and hybrid AK vectors with 
different doses of 5'- and 3'-half vectors (Supp. Fig. 6). We set as 1:1 the dose of 
2.5x108 GC/eye which is submaximal considering that the titers of our AAV preps 
range around 109 GC/L (Supp. Table 2) and that 1 L is the maximum volume 
tolerated by the mouse subretinal space. Thus, 2.5x109 GC/eye which is the high 1:1 
dose (10:10) is the maximum dose which we can administer to the murine eye. We 
show that none of the various ratios tested outperforms the 1:1 ratio of the high dose 
of vectors (10:10) used so far (Supp. Fig. 6). Therefore we used the optimal 10:10 
dose and ratio in our following experiments.  
We then assessed PR-specific transduction levels in C57BL/6 mice following 
subretinal administration of dual AAV TS and hybrid AK vectors, which appears the 
most promising for large gene reconstitution in PR, as well as AAV NS vectors for 
comparison (dose of each vector/eye: 2.4x109 GC). All vectors encoded EGFP under 
the transcriptional control of the PR-specific RHO promoter. One month after vector 
administration whole retina lysates were analyzed by ELISA to quantify EGFP 
protein levels (Fig. 4A). Dual AAV TS and hybrid AK vectors reconstituted 
consistent EGFP expression in PR at levels on average about 16-33 folds lower (6-
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observed in retinal histological sections (Supp. Fig. 4B), and some of the eyes treated 
with dual AAV vectors had EGFP levels in the range of those achieved with AAV NS 
(Fig. 4A). As expected, no detectable EGFP expression was measured by ELISA in 
injected retinas when only one of the dual AAV vectors encoding for EGFP was used 
(n=9: 5 eyes injected with 5’-half and 4 eyes with 3’-half; data not shown).  
Thus, we conclude that dual AAV TS and hybrid AK strategies allow efficient mouse 
PR transduction although at levels which are lower than those obtained with an AAV 
NS. We then confirmed that subretinal administration of dual AAV TS and hybrid 
AK vectors transduced PR of Large White pigs (Fig. 4B; dose of each vector/eye: 
1x1011 GC).  
 
Dual AAV vectors improve the retinal phenotype of STGD and USH1B mouse models. 
To understand whether the levels of PR transduction obtained with the dual AAV TS 
and hybrid AK approaches may be therapeutically relevant, we investigated them in 
the retina of two mouse models of IRDs, STGD and USH1B, caused by mutations in 
the large ABCA4 and MYO7A genes, respectively.  
Although the Abca4-/- mouse model does not undergo severe PR degeneration (Wu et 
al, 2010a), the absence of the ABCA4-encoded all-trans retinal transporter in PR 
outer segments (Illing et al, 1997; Sun & Nathans, 1997) causes an accumulation of 
lipofuscin in PR as well as in RPE, as result of PR phagocytosis by RPE (Mata et al, 
2001; Weng et al, 1999). As a consequence, both the number of lipofuscin granules in 
the RPE and the thickness of RPE cells are greater in Abca4-/- mice than in control 
mice (Allocca et al, 2008; Conley et al, 2012; Han et al, 2012; Ma et al, 2011; Radu et 
al, 2008). In addition, Abca4-/- mice also show delayed recovery from light 
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2008; Weng et al, 1999). Since ABCA4 is expressed specifically in PR, we generated 
dual AAV TS and hybrid AK vectors encoding ABCA4-3xflag under the 
transcriptional control of the RHO promoter. These vectors were subretinally injected 
in wild-type C57BL/6 mice (dose of each vector/eye: 3-5x109 GC) and one month 
later retinas were lysed and analyzed by Western blot with anti-3xflag antibodies (Fig. 
5A). Both approaches resulted in robust yet variable levels of ABCA4-3xflag 
expression. ABCA4-3xflag expression levels were more consistent in retinas treated 
with the dual AAV hybrid AK vectors (Fig. 5A). No truncated and/or aberrant 
ABCA4 proteins were detected by Western blot analysis of C57BL/6 eyecups treated 
with dual AAV TS and hybrid AK vectors using anti-3xflag antibodies although two 
proteins (>100 KDa) smaller than the full length are produced in vitro following 
infection with either the single 5’- or 3’-half of both dual AAV approaches (Supp. Fig. 
7-8). In addition no evident signs of retinal toxicity were observed in Abca4-/- mice at 
8 months after treatment with dual AAV TS and hybrid AK vectors by conventional 
histological analysis (Supp. Fig. 9A).  
To evaluate the biological and therapeutic activity of the recombinant ABCA4 protein 
produced by dual AAV vectors, one month-old albino Abca4-/- mice were injected 
subretinally with the dual AAV TS and hybrid AK RHO-ABCA4-HA vectors (dose of 
each vector/eye: 1-3x109GC). Three months later, eyes were harvested and immuno-
electron microscopy analysis with anti-hemagglutinin (HA) antibodies of retinal 
sections confirmed that immunogold particles were correctly localized in PR outer 
segments only in animals that were injected with the combination of 5’ and 3’ dual 
AAV TS and hybrid AK vectors (Fig. 5B). To assess the functionality of the ABCA4 
protein expressed by the dual AAV vectors, we measured Abca4-/- retinal lipofuscin 
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performed transmission electron microscopy analysis to measure the number of RPE 
lipofuscin granules (Fig. 5C-D) and RPE thickness (Fig. 6A-B). Both were greater in 
the retina of Abca4 -/- mice injected with control vectors (independently of the size of 
the control constructs, Supp. Fig. 10) than in the retina of wild-type, age-matched 
BALB/c controls, and were significantly reduced or normalized in the eyes injected 
either with the therapeutic dual AAV TS or hybrid AK vectors (Fig. 5C-D and 6A-B). 
We additionally attempted at measuring A2E, the major component of lipofuscin 
granules, by HPLC (Allocca et al, 2008; Ben-Shabat et al, 2002; Parish et al, 1998), 
however these measurements were inconsistent, even between affected and normal 
retinas (data not shown), thus we were not able to use these techniques in our rescue 
experiments. Importantly, the eyes treated with dual AAV TS and hybrid AK vectors 
showed improved recovery from light desensitization when compared to eyes treated 
with control vectors (dose of each vector/eye: 1.2x109GC, Fig. 6C), independently of 
the size of the control constructs [Student's t-test p value of dual AAV-EGFP-L (n=2 
TS-L, n=4 AK-L; total n=6) vs dual AAV-EGFP (n=5 TS, n=4 AK; total n=9): 0.23)]. 
We then tested the efficacy of dual AAV-mediated MYO7A gene transfer in the retina 
of sh1 mice, the most commonly used model of USH1B (Gibbs et al, 2010; Lillo et al, 
2003; Liu et al, 1998; Liu et al, 1999; Liu et al, 1997). In sh1 mice, a deficiency in the 
motor Myo7a causes the mis-localization of RPE melanosomes (Liu et al, 1998), 
which do not enter into the RPE apical microvilli, and the accumulation of rhodopsin 
at the PR connecting cilium (Liu et al, 1999). MYO7A is highly expressed in the RPE 
and to a lesser extent in PR (Hasson et al, 1995; Liu et al, 1997), therefore we used 
dual AAV TS and hybrid AK vectors expressing MYO7A-HA under the 
transcriptional control of the ubiquitous CBA promoter. One month-old wild-type 


















1Division of Developmental Immunology, Biocenter, Innsbruck Medical University, 6020 
Innsbruck, Austria;  
2Department of Pediatrics and Adolescent Medicine, Division of Pediatric Hematology and 
Oncology, University Hospital of Freiburg, 79106 Freiburg, Germany;  
3 Section of Molecular Hematology, Department of Hematology/Oncology,  
University Hospital of Freiburg, 79106 Freiburg, Germany;  
4Division of Molecular Pathophysiology, Biocenter, Innsbruck Medical University, 6020 
Innsbruck, Austria; and  
5Department of Obstetrics and Gynecology, University Hospital Freiburg, 79106 Freiburg, 
Germany. 
*These authors contributed equally to this work. 
† current address: Max Delbrück Center for Molecular Medicine (MDC), 13125 Berlin, 
Germany  
Running Title: Bim and Bmf limit stem cell survival 
 
6 Address for correspondence: 
Miriam Erlacher, MD/PhD 
Department of Pediatrics and Adolescent Medicine  
Division of Pediatric Hematology and Oncology 
University Hospital of Freiburg 
79106 FREIBURG (Germany) 
Ph: + 49-761-27043010, Fax: + 49-761-27046230 
E-mail: miriam.erlacher@uniklinik-freiburg.de 
or  
Verena Labi, PhD 
Division of Developmental Immunology,  
Biocenter, Innsbruck Medical University,  
6020 INNSBRUCK (Austria) 
Ph: + 43-512-9003-70380, Fax: + 43-512-9003-73964 
E-mail: verena.labi@mdc-berlin.de 
 
‡This article has been accepted for publication and undergone full peer review but has not  
been through the copyediting, typesetting, pagination and proofreading process, which may 
lead to differences between this version and the Version of Record. Please cite this article as  
doi: 10.1002/emmm.201201235 
 
© 2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. This is an 
open access article under the terms of the Creative Commons Attribution License (CC BY 
3.0), which permits use, distribution and reproduction in any medium, provided the original 
work is properly cited. 
Received: January 25, 2012; Revised: October 5, 2012; Accepted: October 8, 2012 
  16
1.7x109 GC) and eyecup lysates were evaluated one month later using Western blot 
analysis with anti-HA antibodies. Results showed similarly robust and consistent 
levels of MYO7A expression in retinas treated with both approaches (Fig. 7A). 
Taking advantage of our anti-Myo7a antibody able to recognize both murine and 
human MYO7A (although with potentially different affinity for the two orthologous 
proteins), we compared the levels of MYO7A achieved following delivery of dual 
AAV vectors to the sh1-/- eye to those expressed endogenously in the sh1+/- eye (Fig. 
7B). The levels of human MYO7A driven by the CBA promoter one month after 
treatment (Fig. 7B; dose of each vector/eye: 1.7x109GC) were 19-21% of endogenous 
Myo7a expressed in both RPE and PR (Fig. 7B) and these remained similar at 9 
months after vector delivery (MYO7A retinal levels after subretinal delivery of dual 
AAV-TS, quantified on Western blot of eyecup lysates as in Fig. 7B: 19±6% of 
endogenous Myo7a, n=5). Notably, subretinal delivery of dual AAV TS and hybrid 
AK resulted in efficient expression of human MYO7A specifically in PR when using 
the RHO promoter (Supp. Fig. 11). No MYO7A proteins of size different from the 
full-length were detected by Western blot analysis of sh1-/- eyecups treated with 
either dual AAV TS or hybrid AK vectors. However, two proteins smaller than the 
full length MYO7A (<130 KDa) are detected in vitro following infection with either 
the single 5’- or 3’-half of both dual AAV approaches (Supp. Fig. 12-13).  
To test the ability of MYO7A expressed from dual AAV vectors to rescue the defects 
of the sh1-/- retina, we evaluated RPE melanosome (Fig. 8A-B) and rhodopsin 
localization (Fig. 8C) following subretinal injection of dual AAV TS and hybrid AK 
CBA-MYO7A vectors (dose of each vector/eye: 1.7x109 GC) in one month-old sh1 -/- 
mice. Unlike in unaffected sh1 mice, the sh1-/- melanosomes do not enter the RPE 
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AAV strategies, Fig. 8A-B). The number of RPE melanosomes correctly localized 
apically was significantly improved after the delivery of either dual AAV TS or 
hybrid AK vectors encoding MYO7A (Fig. 8B).  
We also found that the number of rhodopsin particles at the connecting cilium is 
greater in sh1-/- retinas treated with control vectors (independently of the size of the 
control constructs, Supp. Fig. 14) than in unaffected sh1 (Fig. 8C and Supp. Fig. 14). 
This was reduced in sh1-/- retinas treated with dual AAV TS and hybrid AK vectors 
expressing MYO7A, although the differences were not statistically significant (Fig. 
8C). Notably, the improvement of the sh1-/- retinal defects is associated with a 
normal retinal architecture (Supp. Fig. 9) which further suggests that subretinal 
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DISCUSSION 
While AAV-mediated gene therapy is effective in animal models and in patients with 
inherited blinding conditions (Bainbridge et al, 2008; Cideciyan et al, 2009; Jacobson 
et al, 2006; Maguire et al, 2009; Maguire et al, 2008; Simonelli et al, 2010), its 
application to diseases affecting the retina and requiring a transfer of genes larger than 
5kb (referred to as large genes) is inhibited by AAV limited cargo capacity. To 
overcome this, we compared the efficiency of various AAV-based strategies for large 
gene transduction including: AAV OZ and dual AAV OV, TS, hybrid AP and AK 
approaches in vitro and in mouse and pig retina. Our in vitro and in vivo results show 
that the dual AAV strategies we tested (with the exception of the dual AAV hybrid 
AP) outperform AAV OZ vectors in terms of transduction levels. This may be 
explained by: i. the homogeneous size of the dual AAV genome population when 
compared to AAV OZ genomes, which may favor the generation of transcriptionally 
active large transgene expression cassettes; ii. the small volume of the subretinal 
space, which we show favors infection and transduction of the same cell by two 
independent AAV vectors. Although this has been suggested by previous work in the 
retina with either dual AAV TS vectors carrying the lacZ reporter gene (Reich et al, 
2003) or with two single vectors encoding different fluorescent reporter proteins 
(Palfi et al, 2012), our study represents the first comprehensive comparison in the 
retina of the dual AAV strategies reported so far, as well as the first demonstration of 
their efficacy in animal models of common inherited blinding conditions. 
The dual AAV OV approach is particularly interesting when compared to the TS or 
hybrid AK approaches, which appear similarly efficient in vitro, as dual AAV OV 
vectors only contain sequences belonging to the therapeutic transgene expression 
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space of adult mice and pigs, we were able to detect expression of the large ABCA4 
and MYO7A proteins only when the ubiquitous or the RPE-specific promoters, but 
not the PR-specific promoters, were used. This may suggest that the homologous 
recombination required for dual AAV OV reconstitution is more efficient in RPE than 
PR. This is consistent with the low levels of homologous recombination reported in 
post-mitotic neurons (Fishel et al, 2007) and may partially explain the low levels of 
dual AAV OV-mediated MYO7A transduction recently reported by other groups 
(Lopes et al, 2013). We conclude that subretinal administration of dual AAV OV 
vectors should not be used for large gene transfer to PR, although we can not exclude 
that sequences that are more recombinogenic than those included in our dual AAV 
OV ABCA4 and MYO7A vectors may allow efficient homologous recombination in 
PR.  
Dual AAV TS and hybrid AK approaches efficiently transduce mouse and pig PR, 
differently from what we observed with dual AAV OV. This is consistent with the 
knowledge that the mechanism of large gene reconstitution mediated by dual AAV 
TS and hybrid AK approaches may be via ITR-mediated head-to-tail rejoining (Duan 
et al, 1998; Ghosh et al, 2008; Yan et al, 2005) rather than homologous recombination.  
The transduction levels provided by the dual hybrid AK are superior to those of the 
TS approach in mouse PR but not RPE. This was evident when using the large 
ABCA4 and MYO7A but not the small EGFP transgene, suggesting an advantage of 
including the AK sequence for large transgene reconstitution in cells like PR which 
are more difficult to target by AAV2/8 than RPE. 
Differently from what we have observed, Hirsch et al. have recently shown that AAV 
OZ vectors can reconstitute a large reporter gene (6.2Kb) in the retina of mice more 
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account for this: i. the design of the dual AAV vectors which may result in lower 
transduction levels in Hirsch et al. than in our case; ii. the purification of the AAV OZ 
vectors by Hirsch et al. that may promote the selection in the viral preparation of 
genomes with higher transduction properties; iii. the use of a shorter transgene by 
Hirsch et al. than by us that gives rise to genomes with longer overlaps which can 
positively influence AAV OZ transduction. Our results also differ from those of 
another group that has reported that dual AAV hybrid AP outperforms TS (Ghosh et 
al, 2011). While we have generated our dual hybrid AP vectors based on the 
description provided in those publications, it is possible that minor differences in the 
AP sequences used may account for the different transduction levels we have 
observed. 
The levels of mouse PR transduction we achieved with dual AAV TS and hybrid AK 
are lower than with single NS vectors. However, we show that in the case of MYO7A, 
retinal transgene expression levels are about 20% of endogenous. These may be 
effective for treating inherited blinding conditions that require relatively low levels of 
transgene expression, i.e. diseases inherited as autosomal recessive. Indeed, we show 
that subretinal delivery of dual AAV TS and hybrid AK improves and even 
normalizes the retinal defects of two animal models of IRDs, STGD and USH1B, 
which are due to mutations in large genes and are attractive targets of gene therapy. 
Importantly, both levels and consistency of dual AAV-mediated large transgene 
expression could be improved by directing the productive head-to-tail genome 
concatemerization by either using heterologous ITRs (Yan et al, 2007) or by adding 
oligos to the injection solution (Hirsch et al, 2009). 
Single normal size AAV vectors ensure multi-year retinal gene expression after a 
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from dual AAV vectors up to 9 months after retinal gene delivery, the last time point 
of our analysis, suggest that longevity of transgene expression may be similar 
between single normal size and dual AAV vectors. 
The genome size of dual AAV vectors is homogeneous, which means identity and 
safety issues related to their use should be less considerable than those related to 
AAV OZ vectors, which have heterogeneous genome sizes. However, the possibility 
that delivery of dual AAV vectors results in the production of aberrant proteins in the 
retina, i.e. truncated proteins from the 5’-half vector that contains the promoter 
sequence and/or from the 3’-half vector due to the low promoter activity of the ITRs 
(Flotte et al, 1993) must be considered. Our results show that proteins smaller than the 
full-length are produced from the 5’- and 3’-halves of dual AAV vectors in vitro but 
not in vivo in the retina where only full-length ABCA4 and MYO7A proteins are 
detected. The production of properly spliced full length proteins by dual AAV vectors 
is corroborated by the successful amplification of the full size ABCA4 and MYO7A 
mRNA retro transcribed from cells infected with dual AAV TS and hybrid AK 
vectors (data not shown). Indeed the transcript sequences confirmed that 
intermolecular AAV joining and splicing occurred correctly (data not shown), as 
expected by the size of the full length proteins detected by Western blot. In addition, 
we detected neither ERG (data not shown) nor retinal histological abnormalities in 
both Abca4-/- and sh1-/- mice that we followed up to 3-8 months after dual AAV 
vector delivery. Future long-term safety studies as well as sensitive proteomic 
profiling will help to better define if any toxicity derives from intraocular 
administration of dual AAV vectors. 
In conclusion, we found that dual AAV vectors are efficient both in vitro and in the 


















1Division of Developmental Immunology, Biocenter, Innsbruck Medical University, 6020 
Innsbruck, Austria;  
2Department of Pediatrics and Adolescent Medicine, Division of Pediatric Hematology and 
Oncology, University Hospital of Freiburg, 79106 Freiburg, Germany;  
3 Section of Molecular Hematology, Department of Hematology/Oncology,  
University Hospital of Freiburg, 79106 Freiburg, Germany;  
4Division of Molecular Pathophysiology, Biocenter, Innsbruck Medical University, 6020 
Innsbruck, Austria; and  
5Department of Obstetrics and Gynecology, University Hospital Freiburg, 79106 Freiburg, 
Germany. 
*These authors contributed equally to this work. 
† current address: Max Delbrück Center for Molecular Medicine (MDC), 13125 Berlin, 
Germany  
Running Title: Bim and Bmf limit stem cell survival 
 
6 Address for correspondence: 
Miriam Erlacher, MD/PhD 
Department of Pediatrics and Adolescent Medicine  
Division of Pediatric Hematology and Oncology 
University Hospital of Freiburg 
79106 FREIBURG (Germany) 
Ph: + 49-761-27043010, Fax: + 49-761-27046230 
E-mail: miriam.erlacher@uniklinik-freiburg.de 
or  
Verena Labi, PhD 
Division of Developmental Immunology,  
Biocenter, Innsbruck Medical University,  
6020 INNSBRUCK (Austria) 
Ph: + 43-512-9003-70380, Fax: + 43-512-9003-73964 
E-mail: verena.labi@mdc-berlin.de 
 
‡This article has been accepted for publication and undergone full peer review but has not  
been through the copyediting, typesetting, pagination and proofreading process, which may 
lead to differences between this version and the Version of Record. Please cite this article as  
doi: 10.1002/emmm.201201235 
 
© 2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. This is an 
open access article under the terms of the Creative Commons Attribution License (CC BY 
3.0), which permits use, distribution and reproduction in any medium, provided the original 
work is properly cited. 
Received: January 25, 2012; Revised: October 5, 2012; Accepted: October 8, 2012 
  22
transduce PR, whereas dual AAV TS and hybrid AK approaches drive efficient large 
gene reconstitution in both cell types. Administration of dual AAV TS and hybrid AK 
approaches improved the retinal phenotype of mouse models of STGD and USH1B, 
providing evidence of the efficacy of these strategies for gene therapy for these and 
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MATERIALS AND METHODS 
Generation of AAV vector plasmids 
The plasmids used for AAV vector production were derived from either the pZac2.1 
(Gao et al, 2000) or pAAV2.1 (Auricchio et al, 2001) plasmids that contain the 
inverted terminal repeats (ITRs) of AAV serotype 2 (Supp. Table 1). Normal size and 
oversize AAV vector plasmids contained full length expression cassettes including 
the promoter, the full-length transgene CDS and the poly-adenylation signal (pA) 
(Supp. Table 1). The two separate AAV vector plasmids (5’ and 3’) required to 
generate dual AAV vectors contained either the promoter followed by the N-terminal 
portion of the transgene CDS (5’ plasmid) or the C-terminal portion of the transgene 
CDS followed by the pA signal (3’ plasmid, Supp. Table 1). Normal size EGFP 
plasmids were generated by cloning the EGFP CDS of pAAV2.1-CMV-EGFP 
plasmid (720 bp) (Auricchio et al, 2001) in pZac2.1 (Gao et al, 2000); oversize EGFP 
was generated from pAAV2.1-CMV-EGFP (Auricchio et al, 2001) by inserting a 
DNA stuffer sequence of 3632 bp from human ABCA4 (NM_000350.2, bp 1960-
5591) upstream of the CMV promoter and a second DNA stuffer sequence of 3621 bp, 
composed of: murine ABCA4  (NM_007378.1, 1066-1 and 7124-6046 bp; 2145 total 
bp) and human Harmonin (NM_153676.3 131-1606 bp; 1476 total bp), downstream 
of the pA signal. To generate dual AAV vector plasmids, the EGFP CDS (720 bp) 
was split into two constructs: one containing the N-terminal CDS (PMID: 9759496, 
bp 1-393) and the other containing the C-terminal CDS (PMID: 9759496, bp 394-
720). The stuffer sequences flanking the EGFP expression cassette in the EGFP OZ 
plasmid were used to generate dual AAV-TS-L and dual AAV-AK-L plasmids (Supp. 
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The oversize ABCA4 plasmids contained the full-length human ABCA4 CDS 
(NM_000350.2, bp 105-6926), while the oversize MYO7A plasmids contained the 
full-length human MYO7A CDS from isoform 1 (NM_000260.3, bp 273-6920). To 
generate plasmids for dual AAV OV vectors the ABCA4 and MYO7A CDS were split 
into two constructs, one containing N-terminal CDS (ABCA4: NM_000350.2, bp 105-
3588; MYO7A: NM_000260.3, bp 273-3782) and the other containing C-terminal 
CDS (ABCA4: NM_000350.2, bp 2819-6926; MYO7A: NM_000260.3, bp 2913-6920). 
Therefore, the region of homology shared by overlapping vector plasmids was 770bp 
for ABCA4 and 870 bp for MYO7A. To generate trans-splicing and hybrid vector 
plasmids the ABCA4 and MYO7A CDS were split at a natural exon-exon junction. 
ABCA4 was split between exons 19-20 (5’ half: NM_000350.2, 105-3022 bp; 3’ half: 
NM_000350.2, bp 3023-6926) and MYO7A was split between exons 24-25 (5’ half: 
NM_000260.3, bp 273-3380; 3’ half:  NM_000260.3, bp 3381-6926). The ABCA4 
and MYO7A proteins were both tagged at their C-terminus: ABCA4 with either the 
3xflag or hemagglutinin (HA) tag; MYO7A with the HA tag only. In addition, the 
ABCA4 protein was tagged at both N- (amino acidic position 590) and C-termini with 
the 3xflag tag for the experiments shown in Supporting Figures 7-8. The splice donor 
(SD) and splice acceptor (SA) signals contained in dual trans-splicing and hybrid 




3’ (SA). The recombinogenic sequence contained in hybrid AP vector plasmids was 
derived from alkaline phosphatase (AP) gene (NM_001632, bp 823-1100), as 
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hybrid AK vector plasmids was derived from the phage F1 genome (Gene Bank 
accession number: J02448.1; bp 5850-5926). The AK sequence is: 5’-
GGGATTTTGCCGATTTCGGCCTATTGGTTAAAAAATGAGCTGATTTAACAA
AAATTTAACGCGAATTTTAACAAAAT-3’. To generate the pZac2.1-CMV-RFP 
plasmid, the monomeric RFP CDS (Campbell et al, 2002) (675bp) was amplified and 
cloned in pZac2.1-CMV-EGFP plasmid using EcoRI and BamHI restriction sites. The 
pAAV2.1-CMV-DsRed plasmid (Palfi et al, 2012) was obtained by cloning the 
DsRed gene from the pDsRed-Express2 plasmid (Clontech, Saint-Germain-en-Laye, 
France) in the pAAV-MCS plasmid (Stratagene, La Jolla, CA, USA). 
The ubiquitous CMV promoter is that contained in pZac2.1 (Gao et al, 2000) or 
pAAV2.1-CMV-EGFP (Auricchio et al, 2001); the ubiquitous CBA promoter was 
derived from pAAV2.1-CBA-EGFP (Mussolino et al, 2011), the PR-specific human 
RHO and RHOK promoters were derived from pAAV2.1-RHO-EGFP and pAAV2.1-
RHOK-EGFP, respectively (Allocca et al, 2007); the RPE-specific VMD2 promoter 
(NG_009033.1, 4870-5470 bp) corresponds to the previously described EcoRI-XcmI 
promoter fragment (Esumi et al, 2004) and was amplified by human genomic DNA. 
The details of cloning strategies as well as plasmid sequences are available upon 
request.  
 
AAV vector production and characterization 
AAV vectors were produced by the TIGEM AAV Vector Core by triple transfection 
of HEK293 cells followed by two rounds of CsCl2 purification (Mueller et al, 2012). 
For each viral preparation, physical titers [genome copies (GC)/mL] were determined 
by averaging the titer achieved by dot-blot analysis (Drittanti et al, 2000) and by PCR 
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al, 2012). The probes used for dot-blot and PCR analyses were designed to anneal 
with either the ITRs or regions within 1Kb from the ITRs. No statistically significant 
differences were found in the titers (GC/mL) of NS AAV2/2 or AAV2/8 compared to 
those of dual AAV OV, TS and hybrid vectors (Supp. Table 2). In addition alkaline 
Southern blot analysis of viral DNA extracted from several dual AAV OV, TS and 
hybrid AK preps showed that the AAV genome is homogeneous and its size 
corresponds to that expected independently of the presence of recombinogenic 
elements in the dual AAV vectors (Supp. Fig. 15). However, since recombination is 
sequence-specific, the conclusions from Supporting Figure 15 can not be directly 
extrapolated to other vectors. The alkaline Southern blot analysis shown in 
Supporting Figure 15 was carried out as follows: 3x1010 GC of viral DNA were 
extracted from AAV particles. To digest unpackaged genomes, the vector solution 
was resuspended in 240 µL of PBS pH 7.4 1X (GIBCO, Invitrogen S.R.L., Milan, 
Italy) and then incubated with 1U/µL of DNase I (Roche, Milan, Italy) in a total 
volume of 300 µL containing 40mM TRIS-HCl, 10mM NaCl, 6mM MgCl2, 1mM 
CaCl2 pH 7.9 for 2 hours at 37°C. The DNase I was then inactivated with 50 mM 
EDTA, followed by incubation with proteinase K and 2.5% N-lauroyl-sarcosil 
solution at 50°C for 45 minutes to lyse the capsids. The DNA was extracted twice 
with phenol-chloroform and precipitated with 2 volumes of ethanol 100% and 10% 
sodium acetate (3M, pH 7). Alkaline agarose gel electrophoresis and blotting were 
performed as previously described (Sambrook & Russell, 2001). Ten µL of the 1 kb 
DNA ladder (N3232L, New England Biolabs, Ipswich, MA, USA) were loaded as 
molecular weight marker. Three different double strand DNA fragments were radio-
labeled with [α-32]-CTP using the Amersham Rediprime II DNA labeling System 
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bp) was generated by digestion of the pZac2.1-CMV-ABCA4_5’ plasmid with EagI; 
the 3’ probe (880 bp) was generated by double digestion of the pZac2.1-
ABCA4_3’_3xflag_SV40 plasmid with StuI and NcoI; the EGFP probe (735 bp) was 
generated by digestion of the pAAV2.1-CMV-EGFP plasmid with NotI and BamHI. 
Prehybridization and hybridization were performed at 65°C in Church buffer 
(Sambrook & Russell, 2001) for 1 hour and overnight, respectively.  Then, the 
membrane (Whatman Nytran N, charged nylon membrane, Sigma-Aldrich, Milan, 
Italy) was washed for 30 minutes in SSC 2X-0.1% SDS and for 30 minutes in SSC 
0.5X-0.1% SDS at 65°C, and then for 30 minutes in SSC 0.1X-0.1% SDS at 37°C. 
The membrane was then analyzed by X-ray autoradiography using Amersham 
HyperfilmTM MP (GE Healthcare Europe, GmbH, Milan, Italy). 
 
AAV infection of HEK293 cells 
HEK293 cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM) 
containing 10% fetal bovine serum and 2 mM L-glutamine (GIBCO, Invitrogen 
S.R.L., Milan, Italy). Cells were plated in six-well plates at a density of 2×106 
cells/well and transfected 16 hours later with 1.3 g of pDeltaF6 helper plasmid 
which contains the Ad helper genes (Zhang et al, 2000) using the calcium phosphate 
method. After 5 hours, cells were washed once with DMEM and incubated with 
AAV2/2 vectors (m.o.i: 105 GC/cell of each vector; 1:1 co-infection with dual AAV 
vectors resulted in of 2x105 total GC/cell) in a final volume of 700 L serum-free 
DMEM. Two hours later 2 mL of complete DMEM were added to the cells. Cells 
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Animal models  
Mice were housed at the Institute of Genetics and Biophysics animal house (Naples, 
Italy) and maintained under a 12-hour light/dark cycle (10-50 lux exposure during the 
light phase). C57BL/6 and BALB/c mice were purchased from Harlan Italy SRL 
(Udine, Italy). Albino Abca4-/- mice were generated through successive crosses and 
backcrosses with BALB/c mice (homozygous for Rpe65 Leu450) (Radu et al, 2004) 
and maintained inbred. Breeding was performed crossing homozygous mice. 
Pigmented shaker1 4626SB/4626SB (referred to as sh1-/-) mice were imported from 
the Wellcome Trust Sanger Institute (Cambridge, UK, a kind gift of Dr. Karen Steel) 
and back-crossed twice with CBA/Ca mice purchased from Harlan Italy SRL (Udine, 
Italy) to obtain heterozygous shaker1 +/4626SB (referred to as sh1+/-) mice to 
expand the colony. The mice were maintained intercrossed; breeding was performed 
crossing heterozygous females with heterozygous males. The pigmented sh1 mice 
used in this study were either affected (sh1-/-) or unaffected (sh1+/- and sh1+/+). 
Albino shaker1 4626SB/4626SB mice (referred as sh1-/-) were imported from the 
Medical Research Council Institute of Hearing Research (Nottingham, UK) and 
maintained inbred; breedings were performed crossing heterozygous female with 
homozygous males. The albino sh1 mice used in this study were either affected (sh1-
/-) or unaffected (sh1+/-). Figure 7B and Supporting Figures 13-14 show data from 
albino sh1-/- mice. The genotype for the MYO7A4626SB allele was performed by PCR 
analysis of genomic DNA (extracted from the mouse tail tip) followed by DNA 
sequencing. The primers used for the PCR amplification are as follows: Fw1 
(GTGGAGCTTGACATCTACTTGACC) and Rev3 
(AGCTGACCCTCATGACTCTGC), which generate a product of 712 bp that was 
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registered as purebred in the LWHerd Book of the Italian National Pig Breeders’ 
Association (Azienda Agricola Pasotti, Imola, Italy). 
 
Subretinal injection of AAV vectors in mice and pigs 
This study was carried out in accordance with the Association for Research in Vision 
and Ophthalmology Statement for the Use of Animals in Ophthalmic and Vision 
Research and with the Italian Ministry of Health regulation for animal procedures. All 
procedures on mice were submitted to the Italian Ministry of Health; Department of 
Public Health, Animal Health, Nutrition and Food Safety on October 17th, 2011. The 
Ministry of Health approved the procedures by silence/consent, as per article 7 of the 
116/92 Ministerial Decree. Surgery was performed under anesthesia and all efforts 
were made to minimize suffering. 
Mice (4-5 weeks-old) were anesthetized with an intraperitoneal injection of 2 mL/100 
g body weight of avertin [1.25% w/v of 2,2,2-tribromoethanol and 2.5% v/v of 2-
methyl-2-butanol (Sigma-Aldrich, Milan, Italy)] (Papaioannou & Fox, 1993), then 
AAV2/8 vectors were delivered subretinally via a trans-scleral trans-choroidal 
approach as described by Liang et al (Liang, 2000). All eyes were treated with 1 L 
of vector solution. The AAV2/8 doses (GC/eye) delivered vary across the different 
mouse experiments as it is described in the “RESULTS” section. To compare dual 
AAV to single AAV NS vectors (Supp. Fig. 1 and Fig. 4A) we used the same dose of 
each vector because we considered that one GC of the 5’-vector plus one GC of the 
3’-vector of dual AAVs are required to re-constitute one full-size functional genome 
as that contained in one particle of AAV NS. To exclude competition between dual 
AAV capsids at the entry step which may lead us to over-estimate the efficiency of 
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GC of AAV2/8 NS-EGFP or 1.7x109 GC of AAV2/8-NS-EGFP + 1.7x109 GC of an 
AAV2/8 vector carrying an unrelated genome (AAV-unrelated, Supp. Fig. 16). 
Notably, we found no significant differences in the levels of EGFP expression 
whether the unrelated AAV was added or not (Supp. Fig. 16), proving that the double 
dose of dual AAV capsids administered when compared to AAV-NS does not affect 
dual AAV-mediated transduction. 
AAV2/1-VMD2-human Tyrosinase (Gargiulo et al, 2009) (dose: 2-5x108 GC/eye) or 
AAV2/5-CMV-EGFP (encoding normal size EGFP, dose: 4x108 GC/eye) were added 
to the AAV2/8 vector solution that was subretinally delivered to albino mice (Abca4-
/-, BALB/c, and sh1; Figs: 5B-D; 6A, B; Supp. Figs. 10, 14) or pigmented sh1 mice 
(Fig. 8), respectively. This allowed us to mark the RPE within the transduced part of 
the eyecup, which was subsequently dissected and analyzed. Subretinal delivery of 
AAV vectors to the pig retina was performed as previously described (Mussolino et al, 
2011). All eyes were treated with 100 L of AAV2/8 vector solution. The AAV2/8 
dose was 1x1010 (Fig. 3B) or 1x1011 GC of each vector/eye (Fig. 4B) and co-injection 
of dual AAV vectors resulted in a total dose of 2x1010 GC/eye or 2x1011 GC/eye, 
respectively.  
 
Western blot analysis & ELISA.  
Samples [(HEK293 cells, retinas or eyecups (cups+retinas)] for Western blot analysis 
were lysed in RIPA buffer (50 mM Tris-HCl pH 8.0, 150mM NaCl, 1% NP40, 0.5% 
Na-Deoxycholate, 1mM EDTA pH 8.0, 0.1% SDS) to extract EGFP and MYO7A 
proteins from HEK293 cells and eyecups, or in SIE buffer (250 mM sucrose, 3 mM 
imidazole pH 7.4, 1% ethanol, and 1% NP-40) to extract MYO7A from retinas and 
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Protease inhibitor cocktail tablets, Roche, Milan, Italy) and 1 mM 
phenylmethylsulfonyl. After lysis EGFP and MYO7A samples were denatured at 
99°C for 5 minutes in 1X Laemli sample buffer; ABCA4 samples were denatured at 
37°C for 15 minutes in 1X Laemli sample buffer supplemented with 4M urea. Lysates 
were separated by 7% (ABCA4 and MYO7A samples) or 12% (EGFP samples) SDS-
polyacrylamide gel electrophoresis. The antibodies used for immuno-blotting are as 
follows: anti-EGFP (sc-8334, Santa Cruz, Dallas, TX, USA, 1:500); anti-3xflag 
(A8592, Sigma-Aldrich, 1:1000); anti-Myo7a (polyclonal, Primm Srl, Milan, Italy, 
1:500) generated using a peptide corresponding to aminoacids 941-1070 of the human 
MYO7A protein; anti-HA antibody (PRB-101P-200, HA.11, Covance, Princeton, NJ, 
USA, 1:2000); anti-Tubulin (T5201,Sigma Aldrich, 1:10000); anti-Filamin A 
(catalog#4762, Cell Signaling Technology, Danvers, MA, USA, 1:1000); anti-
Dysferlin (Dysferlin, clone Ham1/7B6, MONX10795, Tebu-bio, Le Perray-en-
Yveline, France, 1:500). The quantification of EGFP, ABCA4 and MYO7A bands 
detected by Western blot was performed using ImageJ software (free download is 
available at http://rsbweb.nih.gov/ij/). ABCA4 and MYO7A expression was 
normalized to Filamin A or Dysferlin for the in vitro and in vivo experiments, 
respectively. EGFP expression was normalized to Tubulin. Different proteins were 
used for normalization based on the similarity of their molecular weight to those of 
the different transgene products. The TS (Fig. 2D-E), TS-L (Fig. 2F) and NS (Supp. 
Fig. 1) histogram do not have standard error bars as only one TS, TS-L or NS sample 
has been loaded on each SDS-PAGE and used as internal reference sample in each 
independent experiment. To show the internal variability of TS, TS-L and NS samples 
we calculated the expression of proteins as percentage relative to the AK sample (set 
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2F: TS-L=39±6%; Supp. Fig. 1: NS=906±281%. The ELISA was performed on retina 
or eyecup lysates using the Max Discovery Green Fluorescent Protein Kit ELISA 
(Bioo Scientific Corporation, Austin, TX, USA). 
 
Fundus photography 
The fundus live-imaging was performed by dilating the eye of C57BL/6 with a drop 
of tropicamide 1% (Visufarma, Rome, Italy) and subsequent eye stimulation with a 
300W flash. Fundus photographs were taken using a Topcon TRC-50IX retinal 
camera, with a FITC filter, connected to a charge-coupled-device Nikon D1H digital 
camera (Topcon Medical System, Oakland, NJ, USA). 
 
Histology, light and fluorescence microscopy 
To evaluate EGFP expression in histological sections, eyes from C57BL/6 mice or 
Large White pigs (Mussolino et al, 2011) were enucleated one month after AAV2/8 
injection. Mouse eyes were fixed in 4% paraformaldehyde over-night and infiltrated 
with 30% sucrose over-night; the cornea and the lens were then dissected and the 
eyecups were embedded in optimal cutting temperature compound (O.C.T. matrix, 
Kaltek, Padua, Italy). PR co-transduction following subretinal combined delivery of 
AAV2/8-CMV-EGFP and -RFP vectors has been evaluated as follows: retinal 
cryosections from n=6 eyes were analyzed under a fluorescent microscope using 
either the FITC (to visualize EGFP+ cells) or Rhodamine (to visualize RFP+ cells) 
filters. For each eye RFP+ PR contained in one field at 20X magnification (at least 
100) and the corresponding EGFP+ PR (at least 200) were photographed and then 
counted. PR expressing both EGFP and RFP were unequivocally identified based on 
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FITC or Rhodamine filter. To calculate the percentage of co-transduced PR, the 
number of PR expressing both EGFP and RFP was divided by the total number of 
transduced PR, i.e. PR expressing at least one of the two reporter genes. 
Pig eyes were fixed in 4% paraformaldehyde for 48 hours, infiltrated with 10% 
sucrose for 4 hours, 20% sucrose for 4 hours and finally 30% sucrose overnight. Then, 
the cornea, the lens, and the vitreous body were dissected and the EGFP-positive 
portions of the eyecups were embedded in optimal cutting temperature compound 
(O.C.T. matrix, Kaltek). Serial cryosections (12 m thick) were cut along the 
horizontal meridian and progressively distributed on slides. Retinal histology pictures 
were captured using a Zeiss Axiocam (Carl Zeiss, Oberkochen, Germany). Subretinal 
delivery in pigs of AAV vectors encoding for EGFP under the control of the 
Rhodopsin promoter resulted in PR transduction in: 100% of the retinas injected with: 
dual AAV TS (4/4); and dual AAV hybrid AK (3/3, Fig. 4B). 
To analyze melanosome localization in the RPE of pigmented sh1 mice, eyes were 
enucleated 2-3 months following the AAV injection, fixed in 2% glutaraldehyde-2% 
paraformaldehyde in 0.1M phosphate buffer over-night, rinsed in 0.1M phosphate 
buffer and dissected under a florescence microscope. The EGFP-positive portions of 
the eyecups were embedded in Araldite 502/EMbed 812 (catalog #13940, Araldite 
502/EMbed 812 KIT, Electron Microscopy Sciences, Hatfield, PA, USA). Semi-thin 
(0.5 μm) sections were transversally cut on a Leica Ultratome RM2235 (Leica 
Microsystems, Bannockburn, IL, USA), mounted on slides and stained with Epoxy 
tissue stain (catalog #14950, Electron Microscopy Sciences). Melanosomes were 
counted by a masked operator in about 10 different fields/eye under a light 
microscope at 100X magnification. Retinal pictures were captured using a Zeiss 
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Flow Cytometry 
Flow cytometry analysis was carried out as described (Palfi et al, 2012). Briefly, eyes 
in adult 129 mice were subretinally injected with 3 μL of a 1:1 mixture of 3x109 GC 
of AAV2/8-EGFP and 3x109 GC of AAV2/8-DsRed. Control retinas were injected 
with 3 μL of either 3x109 GC of AAV2/8-EGFP or 3 μL of 3x109 GC of AAV2/8-
DsRed or were left un-injected. 3 weeks post-injection, retinas were dissociated in 
trypsin/HBSS, stained with DRAQ5 (Biostatus, Shepshed, UK) and EGFP 
(488:530/40), DsRed (564:615/20) and DRAQ5 (633: 665/20) fluorescence signals 
analyzed in the live cells using a Beckman Coulter Cyan ADP flow cytometer 
(Beckman Coulter Diagnostics Limited, Lismeehan, Ireland) modified by Propel Labs 
(Fort Collins, CO, USA).  The analysis was carried out using Summit v4.3 (Beckman 
Coulter) software.  Nucleated events were selected by gating the brightest DRAQ5 
events in a bivariate density plot of the forward light scatter (FSC) vs DRAQ5.  A 
second selection was done in the bivariate histogram of forward versus side scatter 
(FSC vs SSC), selecting the homogeneous and perfectly well defined population of 
events. Between 10.000 and 25.000 events were analysed per sample. 
 
Electron microscopy and immuno-gold labelling 
For electron microscopy analyses eyes were harvested from Abca4-/- or sh1 mice at 3 
and 2-3 months after AAV injection, respectively. Eyes were fixed in 0.2% 
glutaraldehyde-2% paraformaldehyde in 0.1M PHEM buffer pH 6.9 (240 mM PIPES, 
100 mM HEPES, 8mM MgCl2, 40 mM EGTA) for 2 hours and then rinsed in 0.1 M 
PHEM buffer. Eyes were then dissected under light or fluorescence microscope to 
select the Tyrosinase- or EGFP-positive portions of the eyecups of albino (Abca4-/-, 
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the eyecups were subsequently embedded in 12% gelatin, infused with 2.3M sucrose 
and frozen in liquid nitrogen. Cryosections (50 nm) were cut using a Leica 
Ultramicrotome EM FC7 (Leica Microsystems) and extreme care was taken to align 
PR connecting cilia longitudinally. To avoid bias in the attribution of morphological 
data to the various experimental groups, measurements of RPE thickness and counts 
of lipofuscin granules in Abca4-/- eyes were performed by a masked operator (Roman 
Polishchuk) using the iTEM software (Olympus SYS, Hamburg, Germany). Briefly, 
RPE thickness was measured in at least 30 different areas along the specimen length 
using the “Arbitrary Line” tool of iTEM software. The “Touch count” module of the 
iTEM software was utilized to count the number of lipofuscin granules in the 25μm2 
areas distributed randomly across the RPE layer. The granule density was expressed 
as number of granules per 25μm2. The immuno-gold analysis aimed at testing the 
expression of ABCA4-HA in Abca4-/- samples after AAV vector delivery was 
performed by incubating cryosections successively with monoclonal anti-HA 
antibody (MMS-101P-50, Covance, 1:50), rabbit anti-mouse IgG, and 10-nm gold 
particle-conjugated protein A. To quantify rhodopsin localization to the connecting 
cilium of sh1 PR, cryosections of sh1 mice were successively incubated with anti-
rhodopsin antibody (1D4, ab5417, Abcam, Cambridge, UK, 1:100), rabbit anti-mouse 
IgG, and 10-nm gold particle-conjugated protein A. The quantification of gold density 
of rhodospin in the connecting cilia was performed by a masked operator using iTEM 
software (Olympus SYS). Briefly, the “Touch count” module of the iTEM software 
was used to count the number of gold particles per cilium that were then normalized 
to the cilium perimeter (nm) measured using the “Closed polygon tool”. Gold density 
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under FEI Tecnai-12 (FEI, Eindhoven, The Netherlands) electron microscope 
equipped with a Veletta CCD camera for digital image acquisition.  
 
A2E measurement in Abca4 -/- mice 
To further evaluate lipofuscin accumulation in Abca4-/- mice, we attempted at 
measuring by either HPLC in combination with mass spectrometry (Gutierrez et al, 
2010) or by HPLC alone (Allocca et al, 2008; Ben-Shabat et al, 2002; Parish et al, 
1998) the A2E content of Abca4-/- eyecups which is reported to be increased 




To assess the recovery from light desensitization eyes were stimulated with 3 light 
flashes of 1 cd s/m2 and then desensitized by exposure to constant light (300 cd/m2) 
for 3 minutes. Then, eyes were stimulated over time using the pre-desensitization 
flash (1 cd s/m2) at 0, 5, 15, 30, 45 and 60 minutes post-desensitization. The recovery 
of rod activity was evaluated by performing the ratio between the b-wave generated 
post-desensitization (at the different time points) and that generated pre-
desensitization.  
 
RNA extraction, cDNA production and reverse transcription analyses.  
RNA was extracted at 72 hours after HEK293 cells infection with dual AAV2/2 TS 
and hybrid AK vectors encoding for either ABCA4 or MYO7A (5’+3’halves) and as 
negative controls with either the 5’or 3’half of dual AAV2/2 vectors or with a single 
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Total RNA was extracted using the RT-PCR RNeasy MiniKit (Qiagen, Milan, Italy). 
One g of RNA was submitted to DNase I digestion (RNase Free DNase set, Qiagen) 
and cDNA was generated using the QuantiTect reverse transcription kit (Qiagen). To 
amplify the ABCA4 mRNA region corresponding to the exon-intron junction used in 
dual AAV TS and hybrid AK vectors, one L of cDNA and the following primers 
were used: Abca4_RT_Fw 5’-GCTGGGAAAACCACCACC-3’ and Abca4_RT_Rev 
5’-GTGGACACATGCCAAGGC-3’. A PCR product of the expected size (130 bp) 
was then sequenced. Five L of cDNA were insted used to amplify the full-length 
ABCA4 mRNA (6.9 Kb) with a long-range PCR using TaKaRa LA Taq DNA 
polymerase kit (TaKaRa, Kioto, Japan), and the following primers: ATGFw: 5’- 
GGTACCTCTAGAGTCGACCCGG-3’, which anneals upstream of the ATG start 
codon and SV40polyA-Rev 5’-ACTCATCAATGTATCTTATCATGTCTG-3’. To 
amplify the MYO7A mRNA region corresponding to the exon-intron junction used in 
dual AAV TS and hybrid AK vectors, 1.5 L of cDNA and the following primers 
were used: Fw 5’-AGGGGACAACTACGCACTC-3’ Rev 5’- 
GTCTTCTTGCCCAGGGTCTC-3’. A PCR product of the expected size (218 bp) 
was then sequenced. Two g of total RNA were instead retro-transcribed using 
SuperScript® III First-Strand Synthesis System (Invitrogen) and one L of cDNA 
was used to amplify the full-length MYO7A mRNA (6.7 Kb) with a long-range PCR 
using TaKaRa LA Taq DNA polymerase kit (TaKaRa) and the following primers: 
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Statistical analysis 
Statistical p values ≤0.05 were considered significant. One-way ANOVA with post-
hoc Multiple Comparison Procedure was used to compare data depicted in: Figure 2 
(p ANOVA= A. 0.012; B. 1x10-7; C. 0.002); Figure 4A (p ANOVA=1.9x10-12); 
Figure 6B (p ANOVA=0.00126); Figure 6C (p ANOVA=2.2x10-5); Figure 8B (p 
ANOVA=1.2x10-5); Figure 8C (p ANOVA=0.11); Supporting Figure 1 (p 
ANOVA=2.3x10-8); Supporting Figure 6 (p ANOVA= A: 0.13; B: 0.16); Supporting 
Table 2 (2/2 preps: p ANOVA=0.0698; 2/8 preps: p ANOVA=0.0767). As the counts 
of lipofuscin granules (Fig. 5D) are expressed as discrete numbers, these were 
analyzed by deviance from a Negative Binomial generalized linear models (Venables 
VN & Ripley BD, 2002) (p value analysis of deviance: Fig. 5D: 1.7x10-7). The 
statistically significant differences between groups determined with the post-hoc 
Multiple Comparison Procedure are the following: Fig. 2D: OV vs OZ p=0.03; OV vs 
AP p=0.016. Fig. 2E: OV vs OZ p=0.0001; OV vs AP p=1.1x10-5; OV vs AK 
p=0.0017; TS vs OZ p=1.8x10-5; TS vs AP p=2.3x10-6; TS vs AK p=0.026; AK vs 
OZ p=9x10-7; AK vs AP p=2x10-7. Fig. 2F: AK-L vs OZ p=0.003; AK-L vs TS-L 
p=0.005. Fig4A: NS-EGFP vs TS-EGFP p=0; NS-EGFP vs AK-EGFP p=0. Fig. 5D: 
WT vs Abca4-/- neg p=0.016; WT vs Abca4-/- AK-ABCA4 p=0.03; Abca4-/- neg vs 
Abca4-/- TS-ABCA4 p=0.0005; Abca4-/- neg vs Abca4-/- AK-ABCA4 p=9x10-8. Fig. 
6B: Abca4-/- neg vs Abca4-/- TS-ABCA4 p=0.012; Abca4-/- neg vs Abca4-/- AK-
ABCA4 p=0.002. Fig. 6C (60 min): Abca4-/- neg vs Abca4-/- AK-ABCA4: 0.05; 
Abca4-/- neg vs Abca4-/- TS-ABCA4: 0.009; Abca4-/- AK-ABCA4 vs WT: 0.002; 
Abca4-/- TS-ABCA4 vs WT: 0.02 Abca4-/- neg vs WT 1x10-5. Fig. 8B: sh1+/+ and 
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sh1-/- neg vs sh1-/- TS-MYO7A p=0.0028; sh1-/- neg vs sh1-/- AK-MYO7A p=0.0002. 
Supp. Fig. 1: NS-EGFP vs TS-EGFP p=0; NS-EGFP vs AK-EGFP p=1x10-7. 
The Student’s t-test was used to compare data depicted in Supporting Figure 10, 14 
and 16. The data in the manuscript are depicted as mean ± s.e.m (standard error of the 
mean). The s.e.m has been calculated using the number of independent in vitro 
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THE PAPER EXPLAINED 
 
PROBLEM:  
Inherited retinal degenerations (IRDs) are a common cause of blindness worldwide. 
Gene therapy with AAV vectors is safe and effective in patients with a childhood 
form of IRD. One of the major limitations to extend this clinical success to other 
blinding conditions is that many are caused by mutations in genes with large coding 
sequences that exceed AAV DNA cargo capacity. 
RESULTS: We have generated dual AAV vectors each containing one half of a large 
transgene which is reconstituted upon target cell co-infection by either splicing (trans-
splicing, TS), homologous recombination (overlapping, OV) or a combination of the 
two (hybrid). We show that the delivery of dual AAV TS and hybrid vectors to the 
retina results in efficient reconstitution of large transgenes in mouse and pig 
photoreceptors, the major cell target of IRDs. Although the levels of transgene 
expression achieved with dual AAV vectors are lower than those achieved with a 
single normal size AAV, they result in significant improvement of the retinal disease 
of two mouse models of common IRDs due to mutations in large genes, Stargardt's 
disease (STGD) and Usher syndrome type IB (USH1B).  
IMPACT: Our results provide proof-of-concept of gene therapy for STGD and 
USH1B using dual AAV vectors. Importantly, dual AAV vectors expand AAV cargo 
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FOR MORE INFORMATION 
- Stargardt's disease:  http://www.macular.org/stargardts.htm 
- TREATRUSH (TreatRetUsher): http://www.treatrush.eu/ 
- Online Mendelian Inheritance in Man (OMIM): http://www.ncbi.nlm.nih.gov/omim; 
- Retinal Information Network (RetNet): https://sph.uth.tmc.edu/retnet/ 
Author’s website: http://www.tigem.it/en/research/researchers/alberto-auricchio 
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FIGURE LEGENDS 
Figure 1. Schematic representation of AAV-based strategies for large gene 
transduction. 
CDS: coding sequence; pA: poly-adenylation signal; SD: splicing donor signal; SA: 
splicing acceptor signal; AP: alkaline phosphatase recombinogenic region (Ghosh et 
al, 2011); AK: F1 phage recombinogenic region. Pointed lines show overlapping 
regions available for homologous recombination, dotted lines show the splicing 
occurring between SD and SA. 
 
Figure 2. Dual AAV overlapping, trans-splicing and hybrid AK vectors efficiently 
transduce large genes in vitro. 
Representative Western blot analysis of HEK293 cells infected with AAV2/2 vectors 
encoding for ABCA4 (A, D), MYO7A (B, E) and EGFP (C, F). (A-C) The arrows 
indicate full-length proteins, the micrograms of proteins loaded are depicted under 
each lane, the molecular weight ladder is depicted on the left. (D-F) Quantification of 
ABCA4 (D), MYO7A (E) and EGFP (F) protein bands. The intensity of the ABCA4, 
MYO7A and EGFP bands was divided by the intensity of the Filamin A (D, E) or 
Tubulin (F) bands. The histograms show the expression of proteins as a percentage 
relative to dual AAV trans-splicing (TS) vectors, the mean value is depicted above the 
corresponding bar. Values are represented as mean ± s.e.m. (standard error of the 
mean). (A-F) The Western blot images are representative of and the quantifications 
are from n=4 (A, C, D, F) or n=3 (B, E) independent experiments. OZ: AAV oversize; 
OV: dual AAV overlapping; TS: dual AAV trans-splicing; AP: dual AAV hybrid AP; 
AK: dual AAV hybrid AK; TS-L: dual AAV trans-splicing EGFP with a combined 
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combined genome size similar to OZ-EGFP; 5’+3’: cells co-infected with 5’- and 3’-
half vectors; 5’: control cells infected with the 5’-half vector; 3’: control cells infected 
with the 3’-half vector; α-EGFP: Western blot with anti-EGFP antibody; α-3xflag: 
Western blot with anti-3xflag antibody; α-Myo7a: anti-Myo7a antibody; α-β-Tubulin: 
Western blot with anti-β-Tubulin antibody, used as loading control; α-Filamin A: 
Western blot with anti-Filamin A antibody, used as loading control. *p 
ANOVA<0.05; **p ANOVA<0.001. (E) The asterisks represent significant 
differences with both OZ and AP. (D-F) More details on the TS and TS-L variability 
as well as on the statistical analysis including specific statistical values can be found 
in the Western blot and Statistical analysis paragraphs of the Materials and Methods 
section, respectively. 
 
Figure 3. Dual AAV overlapping vectors transduce RPE but not photoreceptors in the 
mouse and pig retina. 
Representative Western blot analysis of C57BL/6 (A) and Large White pig (B) retinal 
lysates one month following injection of dual AAV2/8 overlapping vectors encoding 
for ABCA4-3xflag (OV) or AAV2/8 vectors expressing EGFP (neg), under the 
control of the ubiquitous cytomegalovirus (CMV) promoter, the PR-specific 
Rhodopsin (RHO) and Rhodopsin kinase (RHOK) promoters, or the RPE-specific 
vitelliform macular dystrophy 2 (VMD2) promoter. The arrows indicate full-length 
proteins, the molecular weight ladder is depicted on the left, 150 micrograms of 
proteins were loaded in each lane. The number (n) and percentage of ABCA4-positive 
retinas out of total retinas analyzed is depicted; α-3xflag: Western blot with anti-
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Figure 4. Dual AAV trans-splicing and hybrid AK efficiently transduce mouse and pig 
photoreceptors.  
(A) EGFP protein quantification by ELISA of retinas from C57BL/6 mice one month 
following subretinal injection of AAV2/8 vectors encoding for EGFP under the 
control of the PR-specific Rhodopsin (RHO) promoter. The scatter plot depicts EGFP 
protein levels from each retina; the mean value for each group is depicted and 
indicated with a solid line. The number (n) of eyes analysed is depicted under the x 
axis. ** p ANOVA<0.001. More details on the statistical analysis including specific 
statistical values can be found in the Statistical analysis paragraph of the Materials 
and Methods section. (B) Fluorescence analysis of retinal cryosections from Large 
White pigs one month following subretinal injection of AAV2/8 vectors encoding for 
EGFP under the control of the PR-specific RHO promoter. The pictures are 
representative of: n=4 or n=3 eyes injected with dual AAV TS or hybrid AK, 
respectively. The scale bar (100 m) is depicted in the figure. NS: AAV normal size; 
TS: dual AAV trans-splicing; AK: dual AAV hybrid AK; DAPI: 4',6'-diamidino-2-
phenylindole staining; EGFP: native EGFP fluorescence; Merge: overlay of DAPI 
and EGFP pictures; RPE: retinal pigmented epithelium; PR: photoreceptors. 
 
Figure 5. Subretinal administration of dual AAV vectors results in ABCA4 expression 
in mouse photoreceptors and reduction in the accumulation of lipofuscin granules in 
Abca4-/- mice. 
(A) Representative Western blot analysis of C57BL/6 retinal lysates one month 
following the injection of dual AAV trans-splicing (TS) and hybrid AK (AK) vectors 
encoding for ABCA4 under the control of the PR-specific Rhodopsin promoter (RHO 
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is depicted on the left, 150 micrograms of protein were loaded in each lane. The 
number (n) and percentage of ABCA4-positive retinas out of total retinas analysed is 
depicted. AK: retinas injected with dual AAV hybrid AK vectors; TS: retinas injected 
with dual AAV TS vectors; neg: retinas injected with AAV vectors expressing EGFP, 
as negative controls; α-3xflag: Western blot with anti-3xflag antibody; α-Dysferlin: 
Western blot with anti-Dysferlin antibody, used as loading control. (B) Representative 
pictures of immuno-electron microscopy analysis with anti-HA antibody of retinal 
sections from wild-type BALB/c (WT) and Abca4-/- mice injected with with either 
dual AAV or with negative control vectors. The black dots represent the immuno-gold 
labelling of the ABCA4-HA protein. The scale bar (200 nm) is depicted in the figure. 
(C) Representative pictures of transmission electron microscopy analysis showing 
lipofuscin granules content in the RPE of WT and Abca4-/- mice injected with either 
dual AAV or negative control vectors. The black arrows indicate lipofuscin granules. 
The scale bar (1.6 m) is depicted in the figure. (D) Quantification of the mean 
number of lipofuscin granules counted in at least 30 fields (25µm2) for each sample. 
The number (n) of eyes analysed is depicted below each bar. The mean value is 
depicted above the corresponding bar. Values are represented as mean ± s.e.m. 
(standard error of the mean). *p ANOVA<0.05. More details on the statistical 
analysis including specific statistical values can be found in the Statistical analysis 
paragraph of the Materials and Methods section. (B-D) WT: BALB/c eyes; Abca4-/- 
neg: Abca4-/- eyes injected with either AAV vectors expressing EGFP (n=2) or the 
5’- (n=3) or 3’- (n=4) half of the dual AAV hybrid AK vectors, as negative control 
(neg total n=9); Abca4-/- AK-ABCA4: mice injected with dual AAV hybrid AK 
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Figure 6. Subretinal injection of dual AAV vectors reduces the thickness of the RPE 
and improves recovery from light desensitization in Abca4-/- mice 
(A) Representative pictures of transmission electron microscopy analysis of retinal 
sections from wild-type BALB/c (WT) and Abca4-/- mice injected with dual AAV 
trans-splicing (TS-ABCA4) and hybrid AK vectors (AK-ABCA4) or with either AAV 
vectors expressing EGFP or 5’-or 3’-half of the dual hybrid AK vectors (neg), as 
negative controls. The dotted lines indicate the edges of RPE cells. The scale bar (3.8 
m) is depicted in the figure. (B) Quantification of the mean RPE thickness counted 
in at least 30 fields for each sample. The number (n) of eyes analysed is depicted 
below each bar. Abca4-/- neg includes Abca4-/- mice injected with either AAV 
vectors expressing EGFP (n=2) or 5’- (n=3) or 3’- (n=4) half of the dual hybrid AK 
vectors (neg total n=9). The mean value is depicted above the corresponding bar. 
Values are represented as mean ± s.e.m (standard error of the mean). (C) Recovery 
from light desensitization in 3 month-old Abca4-/- and BALB/c mice at 6 weeks post-
injection. The relative b-wave is the ratio between the post- and the pre-
desensitization b-wave amplitudes (V) both evoked by 1 cd s/m2. The time (minutes) 
refers to the time post-desensitization. The mean recovery (%) at 60 minutes is 
depicted. WT: BALB/c eyes (n=4); Abca4-/- TS-ABCA4: eyes injected with dual 
AAV TS vectors (n=5); Abca4-/- AK-ABCA4: mice injected with dual AAV hybrid 
AK vectors (n=5); Abca4-/- neg: Abca4-/- mice either not injected (n=2) or injected 
with the 5’-half of the dual AAV TS (n=3) or hybrid AK (n=2) vectors (neg total n=7). 
Values are represented as mean ± s.e.m (standard error of the mean). (B-C) *p 
ANOVA<0.05. More details on the statistical analysis including specific statistical 
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Figure 7. Subretinal administration of dual AAV trans-splicing and hybrid AK vectors 
results in robust MYO7A expression in mice. 
(A) Representative Western blot analysis of C57BL/6 eyecups one month following 
the injection of dual AAV trans-splicing (TS) and hybrid AK (AK) vectors encoding 
for MYO7A-HA under the control of the ubiquitous chicken beta-actin (CBA) 
promoter. The arrow indicates full-length proteins, the molecular weight ladder is 
depicted on the left, 100 micrograms of proteins were loaded in each lane. The 
number (n) and percentage of MYO7A-positive eyecups out of total eyecups analyzed 
is depicted. AK: eyes injected with dual AAV hybrid AK vectors; TS: eyes injected 
with dual AAV TS vectors; neg: eyes injected with either 5’- or 3’-half of the dual 
AAV TS and hybrid AK vectors; α-HA: Western blot with anti-hemagglutinin (HA) 
antibody; α-Dysferlin: Western blot with anti-Dysferlin antibody, used as loading 
control. (B) Quantification of MYO7A levels expressed from dual AAV vectors in 
sh1-/- eyecups relative to endogenous Myo7a expressed in littermate sh1+/- eyecups. 
sh1-/- eyes were injected with dual AAV TS and hybrid AK vectors encoding 
MYO7A under the control of the CBA promoter and analyzed 1.5 months later. 
sh1+/- eyes were injected with AAV vectors expressing EGFP. The number (n) of 
eyes analysed is depicted below each bar. The quantification was performed by 
Western blot analysis using the anti-Myo7a antibody and measurements of MYO7A 
and Myo7a band intensities normalized to Dysferlin. The histograms show the 
expression of MYO7A protein as percentage relative to sh1+/- Myo7a; the mean 
value is depicted above the corresponding bars. Values are represented as mean ± 
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Figure 8. Subretinal administration of dual AAV vectors rescues melanosome and 
rhodopsin localization in sh1-/- retinas.  
(A) Semi-thin retinal sections stained with Epoxy tissue stain representative of 
both sh1+/+ and sh1+/- eyes (sh1+/+) injected with AAV vectors expressing 
EGFP and of sh1-/- eyes injected with dual AAV trans-splicing (TS-MYO7A), 
hybrid AK (AK-MYO7A) or the 5’- or 3’-half vectors (neg), as negative 
controls. The arrows point at correctly localized melanosomes, the scale bar 
(10 m) is depicted in the figure. (B) Quantification of melanosome 
localization in the RPE villi of sh1 mice 2-3 months following subretinal 
delivery of dual AAV vectors. The n of eyes analysed is depicted below each 
bar. The quantification is depicted as the mean number of apical 
melanosomes/100 m, the mean value is depicted above the corresponding 
bar. sh1-/- neg includes sh1-/- eyes injected with AAV vectors expressing 
either 5’- (n=1) or 3’- (n=2) half of the dual TS vectors, or 5’-half (n=2) of the 
dual hybrid AK vectors (neg total n=5). Values are represented as mean ± 
s.e.m. (standard error of the mean). *p ANOVA<0.05, **p ANOVA<0.001. 
(C) Quantification of the number of rhodopsin gold particles at the PR 
connecting cilium of sh1 mice two months following subretinal delivery of 
dual AAV vectors. The n of eyes and connecting cilia analysed is depicted 
below each bar. sh1-/- neg includes sh1-/- eyes injected with AAV vectors 
expressing either 5’-half of the dual TS vectors (n=3) or 5’-half (n=2) of the 
dual hybrid AK vectors (neg total n=5). The quantification is depicted as the 
mean number of gold particles per length of connecting cilium (m), the 
mean value is depicted above the corresponding bar. Values are represented 
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statistical analysis including specific statistical values can be found in the 
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